GO:1904442 negative regulation of thyroid gland epithelial cell proliferation: Signaling Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904442 describes any process that stops, prevents or reduces the frequency, rate or extent of thyroid gland epithelial cell proliferation, including thyroid follicular cells and Hurthle cells.
• TGF-beta signaling is a central negative regulator of thyroid epithelial proliferation, acting through SMAD-dependent and AKT-dependent pathways.
• Loss of negative growth control, such as escape from TGF-beta inhibition, is a hallmark of thyroid tumorigenesis and is linked to thyroid cancer progression.
• Beta-catenin has a Wnt-independent role in thyroid cell proliferation and differentiation, and its dysregulation can override normal growth suppression.
• The term is relevant to thyroid disease research, including thyroid cancer, goiter, and Hurthle cell lesions, where epithelial proliferation is abnormally sustained.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of genes that mediate negative regulation of thyroid epithelial proliferation.
Description
The Gene Ontology (GO) term GO:1904442, negative regulation of thyroid gland epithelial cell proliferation, defines any biological process that stops, prevents or reduces the frequency, rate or extent of proliferation of thyroid gland epithelial cells. Thyroid epithelial cells, including follicular cells and Hurthle cells, are the primary functional units of the thyroid gland, and their controlled proliferation is essential for normal gland homeostasis and response to hormonal cues. Dysregulation of this negative regulation is a key event in thyroid hyperplasia and neoplasia, making the term a focal point for cancer and endocrine research. Mechanistically, negative regulation of thyroid epithelial proliferation is mediated by signaling pathways such as TGF-beta, which can inhibit cell cycle progression through downregulation of cyclin-dependent kinase inhibitors p21 and p27, or via AKT-dependent mechanisms. In some contexts, TGF-beta acts as a potent negative growth regulator, and thyroid epithelial cell clones that escape this control remain inhibited in differentiated functions such as iodide trapping, indicating a dissociation between proliferation and differentiation. Additionally, beta-catenin has been shown to play a Wnt-independent role in thyroid cell proliferation and differentiation, suggesting that multiple signaling nodes converge on this process. For researchers, GO:1904442 provides a structured framework to study how growth-suppressive signals are integrated in thyroid epithelial cells and how their failure contributes to disease. Understanding this term is critical for identifying therapeutic targets in thyroid cancer and for designing experiments that test causal roles of specific genes in proliferation control.
negative regulation of thyroid gland epithelial cell proliferation At A Glance
| GO ID | GO:1904442 |
|---|---|
| GO term | negative regulation of thyroid gland epithelial cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of Hurthle cell proliferation; down-regulation of thyroid follicular cell proliferation; inhibition of thyroid gland epithelial cell proliferation; negative regulation of thyroid follicular cell proliferation |
| Major function | Stops, prevents or reduces the frequency, rate or extent of thyroid gland epithelial cell proliferation |
| Related cell types | Thyroid follicular cells, Hurthle cells (thyroid epithelial cells) |
| Key signaling pathways | TGF-beta signaling, AKT pathway, beta-catenin-mediated regulation |
| Disease relevance | Thyroid cancer, thyroid hyperplasia, Hurthle cell lesions |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:1904442?
GO:1904442 is a biological process term that encompasses any mechanism that negatively regulates the proliferation of thyroid gland epithelial cells. This includes inhibition of cell division, reduction in proliferation rate, or prevention of excessive epithelial expansion in the thyroid gland. The term covers negative regulation of thyroid follicular cell proliferation and Hurthle cell proliferation, as indicated by its synonyms. It is not a molecular function or a cellular component but a higher-level process that integrates signaling pathways, cell cycle control, and tissue-specific growth constraints.
Why Is negative regulation of thyroid gland epithelial cell proliferation Important in Cell Biology?
GO:1904442 is important because loss of negative regulation of thyroid epithelial cell proliferation is a fundamental step in thyroid tumorigenesis. Thyroid cancer is the most common endocrine malignancy, and understanding how normal growth-suppressive mechanisms fail can reveal new therapeutic targets. The term also provides a framework for studying the interplay between proliferation and differentiation in the thyroid, as highlighted by studies showing that thyroid cell clones escaping TGF-beta growth control remain inhibited in iodide trapping. Furthermore, beta-catenin's Wnt-independent role in thyroid proliferation and differentiation underscores the complexity of growth regulation in this tissue. By focusing on this GO term, researchers can systematically investigate genes and pathways that restrain thyroid epithelial expansion, with implications for cancer biology and endocrine physiology.
• Provides a mechanistic framework for understanding how thyroid epithelial proliferation is restrained under normal conditions.
• Loss of negative regulation is a key event in thyroid cancer initiation and progression.
• TGF-beta signaling is a major negative regulator, and its escape is linked to thyroid tumorigenesis.
• Beta-catenin has a Wnt-independent role in thyroid cell proliferation and differentiation, adding another layer of control.
• The term is relevant to Hurthle cell lesions, which are characterized by altered epithelial proliferation.
• Understanding this process can inform targeted therapies for thyroid cancer and other proliferative thyroid diseases.
• It helps dissect the relationship between proliferation arrest and differentiated function, such as iodide trapping.
• CRISPR-based models enable causal testing of candidate genes in this process, accelerating discovery.
• The term is a useful annotation target for functional genomics studies in thyroid biology.
• It bridges endocrine physiology with cancer biology, offering translational opportunities.
What Happens During negative regulation of thyroid gland epithelial cell proliferation?
Initiation by Growth-Suppressive Signals
In simple terms: The process starts when external or internal signals tell thyroid epithelial cells to stop dividing.
Negative regulation of thyroid epithelial proliferation is initiated by growth-suppressive signals such as TGF-beta, which binds to its receptors and activates intracellular cascades. In thyroid cells, TGF-beta acts as a potent inhibitor of proliferation, and clones that escape this control remain inhibited in differentiated functions like iodide trapping, indicating that growth arrest and differentiation can be uncoupled. Additionally, beta-catenin has been shown to play a Wnt-independent role in thyroid cell proliferation and differentiation, suggesting that multiple signaling inputs converge to regulate this process.
Signal Transduction and Cell Cycle Control
In simple terms: Once the stop signal is received, it travels through the cell to block the machinery that drives cell division.
TGF-beta signaling can inhibit thyroid epithelial proliferation by downregulating cyclin-dependent kinase inhibitors p21 and p27 via the AKT pathway, as shown in a mouse model of IFN-gamma deficiency. This pathway modulates the cell cycle machinery, preventing progression through checkpoints. In other contexts, TGF-beta directly inhibits proliferation through SMAD-dependent transcriptional programs. The involvement of AKT suggests cross-talk with survival and metabolic pathways, fine-tuning the proliferation arrest.
Integration with Differentiation Programs
In simple terms: Stopping cell division is often linked to the cell taking on specialized functions, but these can be separated.
In thyroid epithelial cells, negative regulation of proliferation can be dissociated from differentiation. For example, rat thyroid cell clones that escape TGF-beta negative growth control are still inhibited by TGF-beta in their ability to trap iodide, a differentiated function. This indicates that the pathways controlling proliferation and differentiation, while overlapping, are not identical. Beta-catenin also plays a role in both proliferation and differentiation in a Wnt-independent manner, further highlighting the integration of these processes.
Outcomes and Failure in Disease
In simple terms: When this stop process fails, thyroid cells can divide too much, leading to disease.
The ultimate outcome of negative regulation is a reduced rate of thyroid epithelial cell proliferation, maintaining tissue homeostasis. Failure of this process, such as escape from TGF-beta-mediated growth inhibition, is associated with thyroid tumorigenesis. Aberrant expression of regulatory molecules, such as the lncRNA LINC00847, has been linked to thyroid cancer prognosis, suggesting that disruption of negative regulation contributes to malignancy. Thus, understanding the steps of this process is critical for identifying therapeutic targets.
Key Genes Involved in GO:1904442 negative regulation of thyroid gland epithelial cell proliferation
The following genes and proteins have been implicated in the negative regulation of thyroid gland epithelial cell proliferation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Negative growth factor that inhibits thyroid epithelial proliferation | Central to TGF-beta-mediated growth arrest; escape linked to thyroid cancer |
| TGFBR1 | TGF-beta receptor, mediates growth-suppressive signaling | Target for studying TGF-beta pathway in thyroid cells |
| TGFBR2 | TGF-beta receptor, mediates growth-suppressive signaling | Mutations or loss can lead to escape from negative regulation |
| CDKN1A (p21) | Cyclin-dependent kinase inhibitor, blocks cell cycle progression | Downregulated by TGF-beta via AKT in thyroid epithelial cells |
| CDKN1B (p27) | Cyclin-dependent kinase inhibitor, blocks cell cycle progression | Downregulated by TGF-beta via AKT in thyroid epithelial cells |
| AKT1 | Kinase that modulates p21 and p27 levels | Mediates TGF-beta effects on proliferation in IFN-gamma-/- mice |
| CTNNB1 (beta-catenin) | Wnt-independent regulator of thyroid cell proliferation and differentiation | Dysregulation can override growth suppression |
| IFNG | Cytokine that influences TGF-beta effects on proliferation | IFN-gamma deficiency alters TGF-beta signaling in thyroid |
| LINC00847 | Long non-coding RNA associated with thyroid cancer prognosis | Aberrant expression may affect proliferation regulation |
| CRIP2 | Cysteine-rich protein implicated in cell growth regulation | Studied in triple-negative breast cancer; potential analog in thyroid |
| PLA2G4A | Phospholipase A2, produces growth-regulatory metabolites | Novel pathway of cell growth regulation |
| RAS | Oncogene that can evade oncogenic responses in pituitary, relevant to endocrine tumors | Model for studying escape from growth control |
| THRA | Thyroid hormone receptor alpha, mediates hormone effects on development | Thyroid hormone role in Sertoli cell development, mechanistic hypothesis |
| THRB | Thyroid hormone receptor beta, mediates hormone effects | Thyroid hormone signaling in development |
| SMAD2 | TGF-beta signaling effector | Mediates transcriptional responses to TGF-beta in thyroid |
| SMAD3 | TGF-beta signaling effector | Mediates transcriptional responses to TGF-beta in thyroid |
| SMAD4 | Common mediator of TGF-beta signaling | Central to TGF-beta growth inhibition |
| CDKN2A (p16) | Cyclin-dependent kinase inhibitor | Often inactivated in thyroid cancer, contributing to loss of negative regulation |
How Is negative regulation of thyroid gland epithelial cell proliferation Regulated?
The negative regulation of thyroid gland epithelial cell proliferation is itself regulated by multiple signaling pathways. TGF-beta is a primary negative regulator, and its effects can be modulated by cytokines such as IFN-gamma, which influences the downregulation of p21 and p27 via AKT. Beta-catenin, independent of Wnt signaling, also regulates thyroid cell proliferation and differentiation, suggesting cross-talk with other pathways. Additionally, thyroid hormone signaling, through receptors THRA and THRB, plays a role in developmental processes that may impact proliferation. The process can be dysregulated in cancer, where oncogenic pathways such as RAS evade growth-suppressive responses. Understanding these regulatory inputs is essential for identifying points of intervention.
negative regulation of thyroid gland epithelial cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Thyroid cancer, escape from growth inhibition | Knockout of TGFB1 in thyroid cell lines; overexpression of TGF-beta |
| CDKN1A (p21) | Thyroid cancer, cell cycle dysregulation | Point mutation to disrupt CDK inhibitory function; knockout |
| CDKN1B (p27) | Thyroid cancer, cell cycle dysregulation | Knockout in thyroid epithelial cells; rescue with wild-type |
| CTNNB1 (beta-catenin) | Thyroid cancer, Wnt-independent proliferation | Knock-in of stabilized beta-catenin; knockout |
| LINC00847 | Thyroid cancer prognosis | Overexpression and knockout in thyroid cancer cell lines |
Thyroid Cancer
Loss of negative regulation of thyroid epithelial cell proliferation is a hallmark of thyroid cancer. Escape from TGF-beta-mediated growth inhibition allows thyroid cells to proliferate uncontrollably, contributing to tumorigenesis. Aberrant expression of regulatory molecules such as LINC00847 has been associated with poor prognosis in thyroid cancer, indicating that disruption of negative regulation is clinically relevant. Beta-catenin dysregulation, even in a Wnt-independent manner, can also promote proliferation and dedifferentiation.
Hurthle Cell Lesions
Hurthle cell proliferation is explicitly included in the synonyms of GO:1904442, and negative regulation of these cells is important in Hurthle cell neoplasms. While specific studies on Hurthle cell negative regulation are limited, the general mechanisms of TGF-beta and cell cycle control likely apply. Research into this area could uncover distinct regulatory pathways.
Thyroid Hyperplasia and Goiter
Conditions characterized by excessive thyroid epithelial proliferation, such as goiter, may involve impaired negative regulation. Although direct studies are lacking, the pathways described for TGF-beta and cell cycle inhibitors are relevant. Understanding how negative regulation fails could lead to new treatments for hyperplastic thyroid diseases.
From negative regulation of thyroid gland epithelial cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGF-beta signaling abolish negative regulation of thyroid epithelial proliferation? | TGFBR2 knockout in thyroid cell lines (e.g., using CRISPR) |
| Does p21 or p27 downregulation via AKT mediate TGF-beta effects? | Point mutations in AKT phosphorylation sites on p21/p27; knock-in models |
| What is the role of beta-catenin in thyroid proliferation independent of Wnt? | Knock-in of beta-catenin mutants that cannot respond to Wnt; knockout |
| Does LINC00847 regulate thyroid cancer cell proliferation? | Overexpression and knockout of LINC00847 in thyroid cancer cell lines |
| Can restoration of negative regulation suppress thyroid tumor growth? | Inducible overexpression of TGF-beta or p21 in xenograft models |
| What genes are essential for negative regulation in Hurthle cells? | CRISPR library screening in Hurthle cell lines |
How to Study the negative regulation of thyroid gland epithelial cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on proliferation | Identify novel negative regulators in thyroid cells |
| RNA-seq | Transcriptomic changes | Discover downstream targets of TGF-beta and other pathways |
| Phosphoproteomics | Phosphorylation events | Map signaling cascades controlling proliferation arrest |
| EdU incorporation assay | DNA synthesis rate | Quantify proliferation in response to genetic perturbations |
| Western blot | Protein expression levels | Validate p21/p27 downregulation by AKT |
| Immunohistochemistry | Tissue-level proliferation markers | Assess thyroid epithelial proliferation in situ |
| CRISPR activation (CRISPRa) | Gain-of-function effects | Overexpress candidate negative regulators |
| Lentiviral overexpression | Constitutive gene expression | Test if a gene restores negative regulation |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss abolishes negative regulation of thyroid epithelial proliferation, leading to increased proliferation. This approach is powerful for discovering novel regulators and has been applied in cancer research. In thyroid cells, such screens could reveal pathways beyond TGF-beta.
RNA Sequencing (RNA-seq)
RNA-seq can measure transcriptomic changes upon induction of negative regulation, identifying downstream targets of TGF-beta and other pathways. For example, downregulation of p21 and p27 via AKT was demonstrated in a mouse model. RNA-seq can also reveal lncRNAs like LINC00847 that may serve as biomarkers.
Proteomics and Phosphoproteomics
Proteomic approaches can quantify changes in protein abundance and phosphorylation during negative regulation. This is particularly useful for studying AKT-mediated phosphorylation of p21 and p27. Phosphoproteomics can uncover signaling nodes that control proliferation arrest.
Imaging and Proliferation Assays
Live-cell imaging and proliferation assays (e.g., EdU incorporation, MTT) directly measure the rate of thyroid epithelial cell proliferation. These methods can validate findings from genetic screens and confirm the effects of specific genes on negative regulation.
How CRISPR Can Be Used to Study GO:1904442 negative regulation of thyroid gland epithelial cell proliferation
Knockout
CRISPR knockout of candidate genes such as TGFBR2 or CDKN1A can test whether they are required for negative regulation of thyroid epithelial proliferation. Loss of these genes is expected to increase proliferation, mimicking disease states. Knockout models in thyroid cell lines provide a clean background to study pathway dependencies.
Point Mutation
Point mutations can be introduced to disrupt specific phosphorylation sites or functional domains. For example, mutating AKT phosphorylation sites on p21 or p27 can prevent their downregulation, potentially enhancing negative regulation. Such models help dissect precise molecular mechanisms.
Knock-in
Knock-in of tagged or mutant versions of genes (e.g., beta-catenin mutants) allows tracking of protein localization and function in live cells. This is useful for studying Wnt-independent roles of beta-catenin in thyroid proliferation. Knock-in can also model disease-associated mutations.
Overexpression
CRISPR activation or lentiviral overexpression can force expression of negative regulators like TGF-beta or p21 to suppress proliferation. This approach can validate tumor-suppressive functions and test therapeutic potential. Overexpression models are also useful for studying lncRNAs such as LINC00847.
How EDITGENE Supports negative regulation of thyroid gland epithelial cell proliferation Research
Researchers studying negative regulation of thyroid gland epithelial cell proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining proliferation or whether its dysregulation drives disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of thyroid gland epithelial cell proliferation research.
Frequently Asked Questions About negative regulation of thyroid gland epithelial cell proliferation
What is GO:1904442?
GO:1904442 is a Gene Ontology biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of thyroid gland epithelial cell proliferation.
What genes are involved in negative regulation of thyroid gland epithelial cell proliferation?
Key genes include TGFB1, TGFBR1, TGFBR2, CDKN1A (p21), CDKN1B (p27), AKT1, and CTNNB1 (beta-catenin), among others.
How does TGF-beta inhibit thyroid epithelial cell proliferation?
TGF-beta can downregulate p21 and p27 via the AKT pathway, leading to cell cycle arrest in thyroid epithelial cells.
What is the role of beta-catenin in thyroid cell proliferation?
Beta-catenin has a Wnt-independent role in thyroid cell proliferation and differentiation, and its dysregulation can affect growth control.
What diseases are associated with loss of negative regulation of thyroid epithelial proliferation?
Loss of this regulation is linked to thyroid cancer, including Hurthle cell lesions, and may contribute to thyroid hyperplasia.
How can CRISPR be used to study GO:1904442?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in negative regulation of thyroid epithelial proliferation.
What is the synonym for GO:1904442?
Synonyms include negative regulation of thyroid follicular cell proliferation, inhibition of Hurthle cell proliferation, and downregulation of thyroid gland epithelial cell proliferation.
Which pathways regulate negative regulation of thyroid epithelial proliferation?
TGF-beta signaling, AKT pathway, and beta-catenin-mediated regulation are key pathways.
What experimental models are used to study this process?
Thyroid cell lines, primary thyroid epithelial cells, and mouse models with genetic modifications (knockout, knock-in) are commonly used.
Why is GO:1904442 important for cancer research?
Because escape from negative regulation is a hallmark of thyroid cancer, understanding this process can reveal therapeutic targets.
Conclusion
GO:1904442, negative regulation of thyroid gland epithelial cell proliferation, is a critical biological process that maintains thyroid tissue homeostasis. Its dysregulation is intimately linked to thyroid cancer and other proliferative thyroid diseases. Key pathways such as TGF-beta signaling and cell cycle control by p21 and p27 are central to this process, and beta-catenin adds an additional layer of complexity. By leveraging CRISPR-based models and advanced screening technologies, researchers can uncover novel regulators and therapeutic targets. EDITGENE provides the tools and expertise to accelerate this research, from knockout to overexpression and bioinformatics analysis.
References
- 1. Sastre-Perona A et al.. 2014. Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation.. Mol Endocrinol 28(5):681-95 PMID: 24645679
- 2. Holsberger DR et al.. 2005. Understanding the role of thyroid hormone in Sertoli cell development: a mechanistic hypothesis.. Cell Tissue Res 322(1):133-40 PMID: 15856309
- 3. Fang Y et al.. 2012. TGF-β promotes proliferation of thyroid epithelial cells in IFN-γ(-/-) mice by down-regulation of p21 and p27 via AKT pathway.. Am J Pathol 180(2):650-60 PMID: 22119715
- 4. Coppa A et al.. 1995. Epithelial rat thyroid cell clones, escaping from transforming growth factor beta negative growth control, are still inhibited by this factor in the ability to trap iodide.. Cell Growth Differ 6(3):281-90 PMID: 7794796
- 5. Roof AK et al.. 2018. Pituitary somatolactotropes evade an oncogenic response to Ras.. Mol Cell Endocrinol 476:165-172 PMID: 29753028
- 6. Tan Z et al.. 2025. The impact and mechanisms of CRIP2 on the biological behavior of triple-negative breast cancer cells.. Transl Breast Cancer Res 6:32 PMID: 41210648
- 7. Mariggiò S et al.. 2006. A novel pathway of cell growth regulation mediated by a PLA2alpha-derived phosphoinositide metabolite.. FASEB J 20(14):2567-9 PMID: 17060404
- 8. Hei G et al.. 2023. Aberrantly Expressed lncRNA LINC00847 May Serve as a Promising Prognostic Factor for Thyroid Cancer.. Horm Metab Res 55(11):794-800 PMID: 37493640
